>The second reason, the authors noted, is that there isn't significant competition in the U.S. insulin market. Price competition typically comes from the introduction of a generic drug that directly competes with a branded product.
>But the authors said that current insulin makers have blocked the entry to such products by getting new patents based on things such as a new delivery device.
>The second reason, the authors noted, is that there isn't significant competition in the U.S. insulin market. Price competition typically comes from the introduction of a generic drug that directly competes with a branded product.
>But the authors said that current insulin makers have blocked the entry to such products by getting new patents based on things such as a new delivery device.
https://www.usnews.com/news/health-news/articles/2019-11-07/...
Patent reform would help bring generics on the market and reduce prices.